Trial Profile
A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors AbbVie; AbbVie Germany
- 16 Aug 2023 This trial has been completed in Czechia (Date of the global end of the trial: 27-Jun-2019), according to the European Clinical Trials Database record.
- 01 Sep 2021 Results assessing the safety and efficacy of adding veliparib to both CRT and consolidation chemotherapy in this population published in the Lung Cancer
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer